

Please use this diary to record the date, lot numbers, and reason for injection each time you inject Cinryze (Human C1-esterase inhibitor) and share this information with your treating physician at your next visit.

Online Guide to Administration of Cinryze

To support administration training with Cinryze, an online patient guide is available at:
pwa.ltd/Cinryze-pat-ie

If you are a new user you have to set up a user name and password which is needed each time you log-on to the tool. This tool provides:

- A graphical guide to using Cinryze,
- Questionnaires to help you remember the key steps in preparing and using Cinryze and
- Downloadable documents including additional copies of this Patient Diary.

Indications:

Treatment and pre-procedure prevention of hereditary angioedema (HAE) attacks in adults, adolescents and children aged 2 - 12 years old. Routine prevention of angioedema attacks in adults, adolescents and children aged 6 years and over, with severe and recurrent attacks, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

| Date of injection | Time of injection | Vial lot numbers | Expiry date(s) | Reason for injection | Dose Received | Response to Treatment | Adverse Reactions |
|-------------------|-------------------|------------------|----------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------|-----------------------|-------------------|
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |
| | | | | <input type="checkbox"/> Treatment of attack <input type="checkbox"/> Routine prevention <input type="checkbox"/> Pre-procedure | | | |

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the patient information leaflet. Side effects should be reported to the Pharmacovigilance Unit at the Health Products Regulatory Authority (HPRA) at: www.hpra.ie/ Side effects should also be reported to Takeda Products Ireland Ltd. On 1800 937 970 (freephone from Ireland only) or +44 (0)3333 000181 or emailed to: ae.gbr-irl@takeda.com. By reporting side effects you can help provide more information on the safety of this medicine.